<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied 65,521 women with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and 7,420 women with <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> aged ≥ 65 identified from the 16 areas of the Surveillance, Epidemiology and End Results program linked with Medicare data during 1991-2002 </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0948168" disease_type="Disease or Syndrome" abbrv="">Bone marrow toxicity</z:e> associated with chemotherapy was defined using diagnosis codes from Medicare inpatient, outpatient and physician claims </plain></SENT>
<SENT sid="2" pm="."><plain>The time to event Cox regression was utilized to estimate the risk of <z:e sem="disease" ids="C0948168" disease_type="Disease or Syndrome" abbrv="">bone marrow toxicity</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Use of <z:chebi fb="0" ids="48120">anthracyclines</z:chebi>, <z:chebi fb="0" ids="36064">taxanes</z:chebi> or <z:chebi fb="240" ids="33364,33400">platinums</z:chebi> was associated with increased risks of short- (≤3 months) and long-term (&gt;3 months) <z:hpo ids='HP_0001903'>anemia</z:hpo> and <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in patients with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="22333">Alkylating agents</z:chebi> or <z:chebi fb="0" ids="35221">antimetabolites</z:chebi> were additional significant predictors of <z:hpo ids='HP_0001903'>anemia</z:hpo> in women with <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Patients who received chemotherapy (irrespective of regimens) were twice (<z:hpo ids='HP_0003002'>breast cancer</z:hpo>) or three times (<z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e>) as likely to develop <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> compared to those not receiving chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>Among women with <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, patients receiving <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and fluorouracil regimens (hazard ratio=19.0, 95% CI=11.2-32.5), <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>/<z:chebi fb="0" ids="36064">taxane</z:chebi> therapy (21.9, 11.9-40.4) or the <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, adriamycin and fluorouracil regimen (32.5, 19.6-53.9) were strongly associated with risk of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>There was a dose-response relationship between the use of <z:chebi fb="0" ids="36064">taxane</z:chebi> or <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> and the risk of bone marrow suppression, whereas the increased risk of <z:e sem="disease" ids="C0948168" disease_type="Disease or Syndrome" abbrv="">bone marrow toxicity</z:e> was consistently higher in those with use of <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> or <z:chebi fb="0" ids="48120">anthracycline</z:chebi>-based regimens irrespective of the increasing number of cycles received </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, there was an association between chemotherapy use and clinical manifestations of <z:e sem="disease" ids="C0948168" disease_type="Disease or Syndrome" abbrv="">bone marrow toxicities</z:e> in a population-based setting </plain></SENT>
</text></document>